BNP Paribas Financial Markets’s Lexicon Pharmaceuticals LXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$90.7K Buy
37,780
+20,230
+115% +$39.4K ﹤0.01% 4609
2026
Q1
$27.4K Buy
17,550
+17,539
+159,445% +$25.5K ﹤0.01% 4983
2025
Q4
$13 Sell
11
-4,977
-100% -$6.84K ﹤0.01% 5686
2025
Q3
$6.73K Sell
4,988
-3,715
-43% -$4.22K ﹤0.01% 5066
2025
Q2
$8.23K Sell
8,703
-80,411
-90% -$52.1K ﹤0.01% 4888
2025
Q1
$41.1K Buy
89,114
+69,410
+352% +$43.8K ﹤0.01% 4347
2024
Q4
$14.6K Sell
19,704
-12,149
-38% -$14.6K ﹤0.01% 4779
2024
Q3
$50K Buy
31,853
+13,246
+71% +$23.6K ﹤0.01% 3613
2024
Q2
$31.3K Sell
18,607
-40,771
-69% -$73.1K ﹤0.01% 3572
2024
Q1
$143K Buy
59,378
+26,859
+83% +$57.7K ﹤0.01% 3343
2023
Q4
$49.8K Sell
32,519
-88,053
-73% -$105K ﹤0.01% 3567
2023
Q3
$131K Buy
120,572
+95,432
+380% +$167K ﹤0.01% 3248
2023
Q2
$57.6K Buy
25,140
+6,588
+36% +$17.5K ﹤0.01% 3426
2023
Q1
$45.1K Buy
18,552
+10,312
+125% +$23.6K ﹤0.01% 3441
2022
Q4
$15.7K Sell
8,240
-7,219
-47% -$15.4K ﹤0.01% 3570
2022
Q3
$37.1K Sell
15,459
-644
-4% -$1.78K ﹤0.01% 4032
2022
Q2
$30K Sell
16,103
-90,461
-85% -$173K ﹤0.01% 3653
2022
Q1
$223K Buy
106,564
+3,220
+3% +$8.93K ﹤0.01% 3086
2021
Q4
$407K Buy
103,344
+88,103
+578% +$428K ﹤0.01% 3102
2021
Q3
$73.3K Buy
15,241
+12,484
+453% +$51.2K ﹤0.01% 3399
2021
Q2
$12.7K Sell
2,757
-4,041
-59% -$19.5K ﹤0.01% 3665
2021
Q1
$39.9K Sell
6,798
-1,057
-13% -$7.32K ﹤0.01% 3657
2020
Q4
$26.9K Sell
7,855
-1,672
-18% -$3.19K ﹤0.01% 3782
2020
Q3
$13.7K Buy
9,527
+6,653
+231% +$11.8K ﹤0.01% 3917
2020
Q2
$5.73K Sell
2,874
-10,846
-79% -$21.3K ﹤0.01% 3951
2020
Q1
$26.8K Buy
13,720
+7,992
+140% +$23.8K ﹤0.01% 3823
2019
Q4
$23.8K Sell
5,728
-1,986
-26% -$7.64K ﹤0.01% 3947
2019
Q3
$23.2K Buy
7,714
+2,021
+35% +$6.26K ﹤0.01% 3884
2019
Q2
$35.8K Sell
5,693
-4,241
-43% -$25.4K ﹤0.01% 3627
2019
Q1
$55.2K Buy
9,934
+8,979
+940% +$54.5K ﹤0.01% 3446
2018
Q4
$6.34K Sell
955
-1,661
-63% -$13.5K ﹤0.01% 3497
2018
Q3
$27.9K Buy
2,616
+184
+8% +$2.11K ﹤0.01% 3280
2018
Q2
$29.2K Sell
2,432
-6,948
-74% -$71.1K ﹤0.01% 3340
2018
Q1
$80.4K Buy
9,380
+184
+2% +$1.7K ﹤0.01% 3304
2017
Q4
$90.9K Buy
9,196
+4,061
+79% +$42.2K ﹤0.01% 3352
2017
Q3
$63.1K Sell
5,135
-311
-6% -$4.59K ﹤0.01% 3026
2017
Q2
$89.6K Buy
5,446
+4,537
+499% +$70.3K ﹤0.01% 2872
2017
Q1
$13K Sell
909
-464
-34% -$6.88K ﹤0.01% 3128
2016
Q4
$19K Sell
1,373
-2,148
-61% -$34.5K ﹤0.01% 3205
2016
Q3
$63.6K Buy
3,521
+1,873
+114% +$30.1K ﹤0.01% 2324
2016
Q2
$23.6K Buy
+1,648
New +$22.4K ﹤0.01% 2523
2016
Q1
Sell
-9,016
Closed -$120K 2904
2015
Q4
$120K Buy
9,016
+170
+2% +$2.09K ﹤0.01% 2209
2015
Q3
$95K Buy
+8,846
New +$96.6K ﹤0.01% 2427
2015
Q2
Sell
-824
Closed -$5.42K 3588
2015
Q1
$5.42K Buy
+824
New +$5.63K ﹤0.01% 3108
2014
Q4
Sell
-1,921
Closed -$19K 2668
2014
Q3
$19K Buy
+1,921
New +$20.5K ﹤0.01% 3207
2014
Q2
Sell
-150
Closed -$1.61K 3893
2014
Q1
$1.61K Sell
150
-346
-70% -$4.42K ﹤0.01% 2727
2013
Q4
$6.25K Sell
496
-8,555
-95% -$136K ﹤0.01% 2950
2013
Q3
$151K Sell
9,051
-1,902
-17% -$31.9K ﹤0.01% 2335
2013
Q2
$166K Buy
+10,953
New +$166K ﹤0.01% 2403

Other funds holding LXRX

BNP Paribas Financial Markets's LXRX Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Lexicon Pharmaceuticals (LXRX) stake by 115% in Q2 2026, buying an estimated $39.4K and bringing the position to 37,780 shares worth $90.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4609.

BNP Paribas Financial Markets first reported a position in LXRX in Q2 2013 and has held it in 49 quarters since. The position peaked at $407K in Q4 2021. 139 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • BNP Paribas Financial Markets held 37,780 shares of Lexicon Pharmaceuticals worth $90.7K as of Q2 2026.
  • BNP Paribas Financial Markets bought 20,230 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $39.4K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4609 holding.
  • BNP Paribas Financial Markets first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • BNP Paribas Financial Markets's Lexicon Pharmaceuticals position peaked at $407K in Q4 2021.
  • 139 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.